Key facts
- This page summarizes Thomas C. Harding's Form 4 filing for Clovis Oncology, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Apr 2022, 16:16.
Thomas C. Harding - 01 Apr 2022 Form 4 Insider Report for Clovis Oncology, Inc.
- Reporting relationship
- Senior Vice President and Chief Scientific Officer
- Issuer ticker
- N/A
- Reported as of
- 01 Apr 2022
- Net transaction value
- -$18.62
- SEC form
- 4
- Accepted by SEC
- 05 Apr 2022, 16:16:13 UTC
- Prior SEC filing
- 03 Mar 2022
- Next SEC filing
- 03 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas Harding
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thomas C. Harding filed Form 4 for Clovis Oncology, Inc. on 05 Apr 2022.
Change
- Previous filing in this sequence was filed on 03 Mar 2022.
- Current net transaction value: -$18.62.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLVS
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +16
- Change %
- +0.57%
- Price
- Shares after
- 2,838
- Date
- 01 Apr 2022
- Ownership
- By wife
- Footnotes
- F1
CLVS
transaction
Common Stock
Sale
- Transaction value
- $18.62
- Shares
- -7
- Change %
- -0.25%
- Price
- $2.66*
- Shares after
- 2,831
- Date
- 04 Apr 2022
- Ownership
- By wife
- Footnotes
- F2
CLVS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 11,654
- Date
- 01 Apr 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLVS
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -16
- Change %
- -10%
- Price
- $0.000000
- Shares after
- 140
- Date
- 01 Apr 2022
- Ownership
- By wife
- Underlying class
- Common Stock
- Underlying amount
- 16
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each Restricted Stock Unit represents the right to receive one share of Common Stock.
Footnote F2
Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
Footnote F3
Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
SEC remarks
Senior Vice President and Chief Scientific Officer